NKGen Biotech Management

Management criteria checks 1/4

NKGen Biotech's CEO is Paul Y. Song, appointed in Sep 2023, has a tenure of 1.17 years. total yearly compensation is $3.33M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth $71.00K. The average tenure of the management team and the board of directors is 1.1 years and 1.2 years respectively.

Key information

Paul Y. Song

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage	15.0%
CEO tenure	1.2yrs
CEO ownership	0.5%
Management average tenure	1.1yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Y. Song's remuneration changed compared to NKGen Biotech's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$88m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$3m	US$500k	-US$83m
Sep 30 2023	n/a	n/a	-US$56m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$37m	US$366k	-US$27m

Compensation vs Market: Paul Y.'s total compensation ($USD3.33M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Paul Y.'s compensation has been consistent with company performance over the past year.

CEO

Paul Y. Song (58 yo)

1.2yrs

Tenure

US$3,328,322

Compensation

Dr. Paul Y. Song, M.D. joined Calyx Peak Of Ma, Inc. as Chief Medical Officer in 2017. Dr. Song, a board-certified radiation oncologist in Los Angeles and a partnership was formed. He was a Co-Founder & Ch...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Y. Song	CEO & Chairman	1.2yrs	US$3.33m	0.47% $ 71.0k
Yong Man Kim	Chief Scientific Officer	1.2yrs	US$809.26k	0.079% $ 11.8k
James Graf	Interim Chief Financial Officer	1.2yrs	no data	6.78% $ 1.0m
Yoonmi Kang	SVP of Technical Ops & Development	no data	no data	no data
Irene Chang	SVP, HR & Corporate Culture	no data	no data	no data
Denise Chua	SVP of Corporate Affairs	less than a year	no data	no data
Ryan Park	EVP of Financial Planning & Analysis and Corporate Strategy	less than a year	no data	no data
Pierre Gagnon	Advisor	less than a year	no data	no data

1.1yrs

Average Tenure

58.5yo

Average Age

Experienced Management: NKGN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Y. Song	CEO & Chairman	less than a year	US$3.33m	0.47% $ 71.0k
Michael Klowden	Independent Director	1.2yrs	no data	0% $ 0
Kathleen Scott	Independent Director	1.2yrs	no data	0% $ 0
Anthony Reder	Member of Scientific Advisory Board	1.7yrs	no data	no data
Yong Ben	Scientific & Clinical Advisor	no data	no data	no data
Evren Alici	Member of Scientific Advisory Board	no data	no data	no data
Craig Blackstone	Member of Scientific Advisory Board	1.7yrs	no data	no data
Marco Gottardis	Independent Director	less than a year	no data	0% $ 0
Ming Guo	Member of Scientific Advisory Board	1.7yrs	no data	no data

1.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: NKGN's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

NKGen Biotech Management

Management criteria checks 1/4

Key information

Recent management updates

NKGen Biotech, Inc. Announces Board and Committee Elections

NKGen Biotech, Inc. Announces Pierre Gagnon as Chief Operating Officer and as an Officer of the Company

NKGen Biotech, Inc., Annual General Meeting, Aug 28, 2024

NKGen Biotech, Inc., Annual General Meeting, Aug 28, 2024

NKGen Biotech, Inc. Elects Dr. Marco Gottardis as Class I Director, Audit Committee, Compensation Committee and N&Cg Committee

NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee

Recent updates

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech Inc. Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

The Nasdaq Stock Market Notifies NKGen Biotech That it Withdraws the Staff Deficiency Letter

NKGen Biotech, Inc. Announces Board and Committee Elections

NKGen Biotech Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

NKGen Biotech Provides Compliance Update with Nasdaq Listing Rules

NKGen Biotech, Inc. Announces Pierre Gagnon as Chief Operating Officer and as an Officer of the Company

NKGen Biotech Receives Notification from Nasdaq Related to Delayed Quarterly Report

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech, Inc Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference

NKGen Biotech, Inc., Annual General Meeting, Aug 28, 2024

NKGen Biotech, Inc., Annual General Meeting, Aug 28, 2024

NKGen Biotech, Inc. Elects Dr. Marco Gottardis as Class I Director, Audit Committee, Compensation Committee and N&Cg Committee

NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech, Inc.’s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer’s Disease

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP

NKGen Biotech, Inc. announced delayed annual 10-K filing

NKGen Biotech, Inc. announced delayed annual 10-K filing

NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease At the Tau2024 Global Conference

NKGen Biotech Receives Non-Compliance Notice from Nasdaq Regarding Market Value of Listed Securities Requirement

New major risk - Share price stability

NKGen Biotech Receives a Written Notice from the Nasdaq Stock Market

NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee

NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee

High number of new and inexperienced directors

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease

Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease

No independent directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age